U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N5
Molecular Weight 205.2596
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAPIDIL

SMILES

CCN(CC)C1=CC(C)=NC2=NC=NN12

InChI

InChIKey=GSNOZLZNQMLSKJ-UHFFFAOYSA-N
InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C10H15N5
Molecular Weight 205.2596
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19110816

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease. Used to treat patients with ischemic coronary heart, liver, and kidney disease.

CNS Activity

CNS Active
3913
Curator's Comment: Trapidil inhibits CNS remyelination in rats.

Originator

Hydrogenation plant in Rodleben
1
Curator's Comment: Trapidil was first synthesized in1964 by German VEB hydrogenizing in Rodleben in the former German Democratic Republic (GDR), analyzed in subsequent years at the Institute of Pharmacology, Martin Luther University Halle- Wittenberg and in 1971 allowed for the GDR market.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Thrombin-induced Thromboxane formation
1
Target ID: Thrombin-induced Thromboxane formation
Inhibitor
8297
 410.0 µM [IC50]
Antagonist
2778
C-C motif chemokine 2
2
Target ID: P28292
Gene ID: 1.00009128E8
Gene Symbol: CCL2
Target Organism: Oryctolagus cuniculus (Rabbit)
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Trapidil

Approved Use

Trapidil is primarily used for the treatment of coronary heart disease (CHD ) by reducing the preload and afterload of the heart muscle, especially in patients with an intolerance to the standard used ingredients from the class of nitrates. In addition, it decreases after a myocardial infarction, the incidence of other cardiovascular complications. In patients with peripheral arterial occlusive disease Trapidil improves blood flow to the limbs and walking performance.

Launch Date

9.5791677E11
PubMed

PubMed

TitleDatePubMed
Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chronic hyperparathyroidism.
2008 Nov
Patents

Patents

JP2005507711A
1
JP2007508039A
114
JP4758474B2
87
JPS5679674A
1
JPS5718616A
1

Sample Use Guides

In Vivo Use Guide
Adults: Oral: 400-600 mg/day in divided doses
Route of Administration: Oral
In Vitro Use Guide
The addition of 100 to 400 ug/ml Trapidil significantly reduced cell proliferation induced by different growth factors (FCS, PDGF-BB, bFGF, EGF)
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:51 UTC 2023
Edited
by admin
on Fri Dec 15 15:48:51 UTC 2023
Record UNII
EYG5Y6355E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAPIDIL
EP   INN   MART.   MI   WHO-DD  
INN  
Official Name English
TRAPIDIL [MI]
Common Name English
Trapidil [WHO-DD]
Common Name English
AR 12008
Code English
ROCORNAL
Brand Name English
TRAPIDIL [JAN]
Common Name English
TRAPIDIL [MART.]
Common Name English
trapidil [INN]
Common Name English
AR-12008
Code English
TRAPIDIL [EP MONOGRAPH]
Common Name English
7-(DIETHYLAMINO)-5-METHYL-S-TRIAZOLO(1,5-A)PYRIMIDINE.
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC01DX11
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
NCI_THESAURUS C744
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
WHO-ATC C01DX11
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
Code System Code Type Description
MESH
D014192
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
MERCK INDEX
m11005
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB09283
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
CAS
15421-84-8
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
NCI_THESAURUS
C66615
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
RXCUI
10735
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
3621
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL132767
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
INN
3402
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
239-434-2
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
WIKIPEDIA
TRAPIDIL
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
EVMPD
SUB11220MIG
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID0045416
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
FDA UNII
EYG5Y6355E
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
PUBCHEM
5531
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
SMS_ID
100000091916
Created by admin on Fri Dec 15 15:48:51 UTC 2023 , Edited by admin on Fri Dec 15 15:48:51 UTC 2023
PRIMARY
Related Record Type Details
Structure of 5-METHYL-(1,2,4)TRIAZOLO(1,5-A)PYRIMIDIN-7(1H)-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of AMITROLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of TRAPIDIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966